Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders

Inclusion Criteria

• •All Subjects must:
• •1. Be willing to have samples collected and stored for future research.
• •2. Have a documented clinical history compatible with EGID, peanut allergy, or other allergic and inflammatory diseases or be healthy without known allergic conditions.
• •Subjects with EGID must:
• •1. Be greater than or equal to 18 years of age
• •2. Maintain a primary non-NIH physician for routine care
• •3. Have one of the types of EGID below:
• •* Eosinophilic gastroenteritis: Have a clinical history of eosinophilic gastroenteritis -including gastrointestinal symptoms-, and histological evidence of stomach or duodenal eosinophilia with no other known etiology for the eosinophilia despite careful clinical evaluation.
• •OR
• •Eosinophilic esophagitis: Have a diagnosis of eosinophilic esophagitis, including evidence of esophageal dysfunction with a peak count of greater than or equal to 25 eosinophils per high powered field, for which the biopsy was obtained while under proton pump inhibitor treatment.
• •OR
• •Probable eosinophilic esophagitis: Have a likely diagnosis of eosinophilic esophagitis, based on evidence of esophageal dysfunction and a peak count of greater than or equal to 15 eosinophils per high powered field, but for which the biopsy was not obtained under proton pump inhibitors (per section 6.3). To confirm
• •a diagnosis of EoE, these subjects may be treated with proton pump inhibitor therapy at recommended doses for gastroesophageal reflux disease for at least 84 weeks prior to EGD and biopsy. The decision to recommend diagnostic biopsy will be according to concensus guidelines \[7\] and current standards of care: based on the severity of symptoms, history of food impactions, and evidence of remodeling (strictures).
• •Subjects with Peanut Allergy:
• •1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age.
• •2. Have a history of immediate hypersensitivity to peanuts with involvement of at least one extracutaneous site, including wheezing, laryngeal edema, angioedema, vomiting, diarrhea, hypotension and circulatory collapse.
• •3. Have peanut specific IgE of greater than or equal to 5 kIU/L.
• •Subjects with Other Allergic and Inflammatory Diseases:
• •1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age.
• •2. These subjects must be diagnosed with an allergic or an inflammatory disease, including anaphylaxis, asthma, or hay fever. Diagnosis will be based on established criteria for each clinical entity.
• •Healthy, Non-Atopic Subjects:
• •1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age.
• •2. Have no history of allergies, asthma or food allergy
• •3. Have a negative ImmunoCAP fx5 in vitro food allergy screen for allergen specific IgE to egg white, milk, cod, wheat, peanut, and soy
• •4. Have a negative Phadiatop allergy screen